At a glance
ClinicalIndex Comparison RecordN/ACompleted· 419 enrolled
Drug / intervention
bimatoprost 0.01% ophthalmic solutiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
In Brief
An observational study evaluating bimatoprost 0.01% ophthalmic solution for Glaucoma, Open-Angle and Ocular Hypertension. Completed, enrolled 419 participants across 1 site.
Detailed Summary
A study of Lumigan® 0.01% as administered in standard practice for patients with POAG or OHT. All treatment decisions, care and diagnostic procedures provided are at the discretion of the participating physicians according to their clinical judgment and the local standard of medical care.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Open-Angle, Ocular Hypertension
CountriesAustria
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2012
First PostedMay 2012
Primary CompletionFeb 2013
TodayJul 2026
First PostedMay 2, 2012
Enrollment StartApr 1, 2012
Primary CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 14.2 years ago
Interventions
bimatoprost 0.01% ophthalmic solutiondrug
Bimatoprost 0.01% ophthalmic solution (Lumigan® 0.01%) as prescribed by physician per standard practice for up to 14 weeks.